Nampt/PBEF/visfatin and cancer

被引：169

作者：

Bi, Tie-qiang ^{[1
]}

Che, Xiang-ming ^{[1
]}

机构：

[1] Xi An Jiao Tong Univ, Dept Gen Surg, Affiliated Hosp 1, Sch Med, Xian 710049, Shaanxi, Peoples R China

来源：

CANCER BIOLOGY & THERAPY | 2010年 / 10卷 / 02期

关键词：

Nampt/PBEF/visfatin; carcinogenesis; cancer chemotherapy; DNA damage; signaling pathway; apoptosis; clinical trial; NICOTINAMIDE ADENINE-DINUCLEOTIDE; PYRIDYL CYANOGUANIDINE CHS-828; POTENT ANTITUMOR-ACTIVITY; IN-VITRO; NAD BIOSYNTHESIS; CELL-DEATH; PHASE-I; MMP-2/9; PRODUCTION; ENDOTHELIAL-CELLS; AGENT CHS-828;

D O I：

10.4161/cbt.10.2.12581

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Nampt/PBEF/visfatin is the rate-limiting enzyme that catalyzes the first step in NAD biosynthesis from nicotinamide and regulates growth, apoptosis and angiogenesis of mammalian cells. This enzyme was originally cloned as a putative cytokine shown to enhance the B cell precursor maturation in the presence of IL-7 and stem cell factor. A number of cancers have increased expression of Nampt/PBEF/visfatin, which regulates a variety of different signaling pathways such as PI3K/Akt, ERK1/2 and STAT3. FK866/APO866 and CHS828/GMX1777 are two known inhibitors of Nampt/PBEF/visfatin and have been evaluated as anticancer agents in the clinic. This review will focus on its role in carcinogenesis and cancer progression and its inhibitors as therapeutic target for cancer treatment.

引用

页码：119 / 125

页数：7

共 75 条

[1] Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis [J].

Adya, Raghu ;

Tan, Bee K. ;

Punn, Anu ;

Chen, Jing ;

Randeva, Harpal S. .

CARDIOVASCULAR RESEARCH, 2008, 78 (02) :356-365

[2] Nuclear factor-κB induction by visfatin in human vascular endothelial cells -: Its role in MMP-2/9 production and activation [J].

Adya, Raghu ;

Tan, Bee K. ;

Chen, Jing ;

Randeva, Harpal S. .

DIABETES CARE, 2008, 31 (04) :758-760

[3] Activity of CHS 828 in primary cultures of human hematological and solid tumors in vitro [J].

Åleskog, A ;

Bashir-Hassan, S ;

Hovstadius, P ;

Kristensen, J ;

Höglund, M ;

Tholander, B ;

Binderup, L ;

Larsson, R ;

Jonsson, E .

ANTI-CANCER DRUGS, 2001, 12 (10) :821-827

[4] The PARP superfamily [J].

Amé, JC ;

Spenlehauer, C ;

de Murcia, G .

BIOESSAYS, 2004, 26 (08) :882-893

[5] Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1 [J].

Bae, Soo-Kyung ;

Kim, Su-Ryun ;

Kim, Jong Gab ;

Kim, Jee Yeon ;

Koo, Tae Hyeon ;

Jang, Hye-Ock ;

Yun, Il ;

Yoo, Mi-Ae ;

Bae, Moon-Kyoung .

FEBS LETTERS, 2006, 580 (17) :4105-4113

[6] Nicotinamide phosphoribosyltransferase and prostaglandin H2 synthase 2 are up-regulated in human pancreatic adenocarcinoma cells after stimulation with interleukin-1 [J].

Bauer, Lukas ;

Venz, Simone ;

Junker, Heike ;

Brandt, Rowena ;

Radons, Juergen .

INTERNATIONAL JOURNAL OF ONCOLOGY, 2009, 35 (01) :97-107

[7] Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777 [J].

Beauparlant, Pierre ;

Bedard, Dominique ;

Bernier, Cynthia ;

Chan, Helen ;

Gilbert, Karine ;

Goulet, Daniel ;

Gratton, Michel-Olivier ;

Lavoie, Manon ;

Roulston, Anne ;

Turcotte, Emilie ;

Watson, Mark .

ANTI-CANCER DRUGS, 2009, 20 (05) :346-354

[8] Poly(ADP-ribosyl)ation inhibitors:: Promising drug candidates for a wide variety of pathophysiologic conditions [J].

Beneke, S ;

Diefenbach, J ;

Bürkle, A .

INTERNATIONAL JOURNAL OF CANCER, 2004, 111 (06) :813-818

[9] MODULATION OF NICOTINAMIDE ADENINE-DINUCLEOTIDE AND POLY(ADENOSINE DIPHOSPHORIBOSE) METABOLISM BY THE SYNTHETIC C-NUCLEOSIDE ANALOGS, TIAZOFURIN AND SELENAZOFURIN - A NEW STRATEGY FOR CANCER-CHEMOTHERAPY [J].

BERGER, NA ;

BERGER, SJ ;

CATINO, DM ;

PETZOLD, SJ ;

ROBINS, RK .

JOURNAL OF CLINICAL INVESTIGATION, 1985, 75 (02) :702-709

[10] BIOCHEMICAL AND ANTITUMOR-ACTIVITY OF TIAZOFURIN AND ITS SELENIUM ANALOG (2-BETA-D-RIBOFURANOSYL-4-SELENAZOLECARBOXAMIDE) [J].

BORITZKI, TJ ;

BERRY, DA ;

BESSERER, JA ;

COOK, PD ;

FRY, DW ;

LEOPOLD, WR ;

JACKSON, RC .

BIOCHEMICAL PHARMACOLOGY, 1985, 34 (07) :1109-1114

← 1 2 3 4 5 6 7 8 →